Is Vir Biotechnology (VIR) Cheap On Fast Track News And SOLSTICE Data Hopes?
Vir Biotechnology (VIR) has moved back into focus after the FDA granted Fast Track designation to its prostate cancer candidate VIR-5500, alongside fresh attention on upcoming hepatitis delta data from the SOLSTICE trial.
Vir Biotechnology’s recent clinical updates have arrived alongside a sharp rebound in its shares, with a 1-month share price return of 8.23% and a 90-day move of 17.47%. The stock shows strong short-term momentum but a mixed longer-term picture, given the 5-year total shareholder return decline of 70.07%.
Scan Vir Biotechnology’s momentum against a curated field of late-stage and catalyst driven biotech names by checking the 20 high quality undiscovered gems that are still flying under most investors’ radar.
Vir Biotechnology has already rerated on fresh clinical momentum, yet the share price still reflects a heavy 5 year drawdown. Is this the moment to lean into the reset, or does patience on the entry price make more sense?
Most Popular Narrative: 46% Undervalued
Against a last close of $11.70, the most followed narrative pegs Vir Biotechnology’s fair value at $21.56, which implies a wide gap that hinges on hepatitis delta and oncology delivering over time.
The analysts have a consensus price target of $21.56 for Vir Biotechnology based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $171.2 million, earnings will come to $32.5 million, and it would be trading on a PE ratio of 169.1x, assuming you use a discount rate of 7.3%.
See why 13 investors see Vir Biotechnology as 46% undervalued.
Result: Fair Value of $21.56 (UNDERVALUED)
Still, the bullish Vir Biotechnology story can unravel quickly if key hepatitis delta or oncology trials disappoint, or if regulatory or legal setbacks escalate.
Find out about the key risks to this Vir Biotechnology narrative.
Next Steps
Sentiment around Vir Biotechnology is split, and this is exactly why it can be useful to review the numbers yourself and stress test the assumptions before reacting to the headlines. To see what issues are already on the radar, take a closer look at the 3 important warning signs.
Looking for more investment ideas beyond Vir Biotechnology?
If Vir Biotechnology has your attention, do not stop there. Broaden your watchlist and keep fresh ideas coming using targeted stock screeners built for fundamentals.
- Spot potential mispricings early by scanning the 28 high quality undervalued stocks that combine quality fundamentals with discounted market pricing.
- Strengthen portfolio resilience by reviewing the list of solid balance sheet and fundamentals (25 results) that pair healthier finances with cleaner balance sheets.
- Dial down portfolio stress by focusing on the 31 resilient stocks with low risk scores that already score well on risk metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com